ArticleSkin health and disease2025
Effective management of psoriasis and psoriatic arthritis in a patient with systemic lupus erythematosus using deucravacitinib, mycophenolate mofetil and hydroxychloroquine.
Article in Skin health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systemic Treatment Strategies for Patients with Psoriasis and Psoriatic Arthritis in the Setting of ANA Positivity or Lupus Spectrum Disease: A Comprehensive Systematic Review.International journal of molecular sciences · 2026Pooled it
- Management Considerations for Patients with Hidradenitis Suppurativa and Lupus Spectrum Disease: A Narrative Review.Dermatology and therapy · 2026Review
- Deucravacitinib in dermatology: current indication and existing off-label data.Drugs in context · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report the case of a 32-year-old woman with severe psoriasis, psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE), including lupus nephritis. Despite effective control of her SLE and PsA with hydroxychloroquine, mycophenolate mofetil (MMF) and belimumab, her psoriatic skin manifestations worsened over time. The differing therapeutic responses of these two autoimmune diseases are rooted in their distinct pathogenesis: SLE treatments target B cells, autoantibodies and interferon signalling, while psoriasis requires therapies inhibiting the interleukin (IL)-23/IL-17 axis or tumour necrosis factor-α to address cutaneous inflammation and keratinocyte proliferation. There is limited evidence suggesting that MMF may suppress joint inflammation in PsA, but it does not effectively control psoriatic skin manifestations. Given the negative impact on her quality of life, deucravacitinib, a selective tyrosine kinase 2 inhibitor, was initiated at the approved dose of 6 mg daily. To avoid overimmunosuppression, belimumab was halted. Within 3 months, the patient's Psoriasis Area and Severity Index (PASI) improved from 23 to 1.2, body surface area from 70% to 2% and Dermatology Life Quality Index (DLQI) from 15 to 2, with no joint pain and no SLE flare-ups. After 6 and 9 months, her skin manifestations remained in remission (PASI 1.2 and PASI 0, respectively), DLQI was 0 and joint symptoms remained fully controlled. No significant side effects or infections were observed. These findings suggest deucravacitinib may offer an effective treatment alternative for patients with overlapping autoimmune diseases, without compromising SLE control or increasing infection risk.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.